NL-OMON30449已完成2 期
evetiracetam (Keppra®) in neonates -
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •·newborn gestational age >= 37 weeks, birth weight > 1500 grams
- •·refractory to phenobarbitone up to 40 mg/kg or refractory to phenobarbitone up to 40 mg/kg and midazolam up to 0.5 mg/kg (raised from 0.1 mg/kg every 10-15 minutes when effect fails)
- •·after correction or treatment of metabolic causes as inborn errors, hypoglycemia or hypocalcaemia or CNS infections
排除标准
- •·newborn gestational age < 37 weeks, birth weight < 1500 grams
研究者
相似试验
进行中（未招募）
不适用
evetiracetam (Keppra®) in neonatesepileptic seizures in neonates admitted to the intensive care unitMedDRA version: 9.1Level: LLTClassification code 10041350Term: Somnolence neonatalMedDRA version: 9.1Level: LLTClassification code 10013573Term: DizzinessMedDRA version: 9.1Level: LLTClassification code 10004210Term: Behavioural disorderEUCTR2006-006804-12-NLErasmusMedical Center-Sophia
已完成
不适用
evetiracetam (Keppra®) in neonates: safety of intravenous levetiracetam for neonates with seizureseonatal seizuresNervous System DiseasesEpisodic and paroxysmal disordersISRCTN53371491Erasmus Medical Centre (The Netherlands)10
招募中
3 期
evetiracetam for management of seizures in newborCTRI/2013/04/003585Rainbow Childrens Hospital100
进行中（未招募）
不适用
evetiracetam Keppra in the dyskinesias induced from levodopa in patients with disease of Parkinson. Clinical study pilot in open, with farmacokinetic-farmacodynamic monitoring of the effects.Treatment of the induced coreiche dyskinesias from the therapy with levodopa in patients with Disease of Parkinson.MedDRA version: 6.1Level: PTClassification code 10028035EUCTR2005-002208-40-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI12
已完成
3 期
To see if Levetiracetam, a new seizure control medication is better over older medication Phenobarbitone for immediate neonatal seizure control.CTRI/2015/06/005849Dr Nikhil D Kulkarni38